What is a stock summary page? Click here for an overview.
Business Description
Concord Biotech Ltd
ISIN : INE338H01029
Compare
Compare
Traded in other countries / regions
543960.India IPO Date
2023-08-18Description
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 92.97 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-EBITDA | 0.01 | |||||
| Interest Coverage | 451.75 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 64.25 | |||||
| Beneish M-Score | -2.18 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 18.2 | |||||
| 3-Year EBITDA Growth Rate | 11.2 | |||||
| 3-Year EPS without NRI Growth Rate | 9 | |||||
| 3-Year Book Growth Rate | 15.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 24.51 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 20.18 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.47 | |||||
| 9-Day RSI | 42.11 | |||||
| 14-Day RSI | 40.42 | |||||
| 3-1 Month Momentum % | -0.22 | |||||
| 6-1 Month Momentum % | 1.72 | |||||
| 12-1 Month Momentum % | 54.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.6 | |||||
| Quick Ratio | 4.83 | |||||
| Cash Ratio | 2.25 | |||||
| Days Inventory | 296.54 | |||||
| Days Sales Outstanding | 109.25 | |||||
| Days Payable | 110.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.53 | |||||
| Dividend Payout Ratio | 0.28 | |||||
| Forward Dividend Yield % | 0.53 | |||||
| 5-Year Yield-on-Cost % | 0.52 | |||||
| Shareholder Yield % | 0.62 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 74 | |||||
| Operating Margin % | 37.84 | |||||
| Net Margin % | 30.48 | |||||
| FCF Margin % | 16.8 | |||||
| ROE % | 21.89 | |||||
| ROA % | 19.51 | |||||
| ROIC % | 23.27 | |||||
| 3-Year ROIIC % | 16.06 | |||||
| ROC (Joel Greenblatt) % | 36.11 | |||||
| ROCE % | 28.96 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 53.76 | |||||
| Forward PE Ratio | 40 | |||||
| PE Ratio without NRI | 53.76 | |||||
| Price-to-Owner-Earnings | 93.87 | |||||
| PS Ratio | 16.39 | |||||
| PB Ratio | 11.04 | |||||
| Price-to-Tangible-Book | 10.85 | |||||
| Price-to-Free-Cash-Flow | 97.59 | |||||
| Price-to-Operating-Cash-Flow | 66.1 | |||||
| EV-to-EBIT | 38.41 | |||||
| EV-to-EBITDA | 34.27 | |||||
| EV-to-Revenue | 15.82 | |||||
| EV-to-FCF | 98.7 | |||||
| Price-to-Graham-Number | 5.04 | |||||
| Price-to-Net-Current-Asset-Value | 22.67 | |||||
| Price-to-Net-Cash | 119.43 | |||||
| Earnings Yield (Greenblatt) % | 2.6 | |||||
| FCF Yield % | 1.05 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Concord Biotech Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 10,702.906 | ||
| EPS (TTM) (₹) | 31.19 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 47.9 | ||
| 14-Day RSI | 40.42 | ||
| 14-Day ATR (₹) | 116.533466 | ||
| 20-Day SMA (₹) | 1765.555 | ||
| 12-1 Month Momentum % | 54.44 | ||
| 52-Week Range (₹) | 1326.9 - 2658 | ||
| Shares Outstanding (Mil) | 104.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Concord Biotech Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Concord Biotech Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Concord Biotech Ltd Frequently Asked Questions
What is Concord Biotech Ltd(BOM:543960)'s stock price today?
The current price of BOM:543960 is ₹1648.15. The 52 week high of BOM:543960 is ₹2658.00 and 52 week low is ₹1326.90.
When is next earnings date of Concord Biotech Ltd(BOM:543960)?
The next earnings date of Concord Biotech Ltd(BOM:543960) is .
Does Concord Biotech Ltd(BOM:543960) pay dividends? If so, how much?
The Dividend Yield %  of Concord Biotech Ltd(BOM:543960) is 0.53% (As of Today), Highest Dividend Payout Ratio of Concord Biotech Ltd(BOM:543960) was 0.28. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Concord Biotech Ltd(BOM:543960) is 0.53%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers